Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
$0.1439
Day's Change
0.0389 (37.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.229
Day's Low
0.1301
Volume
(Heavy Day)
Volume:
83,434,571

10-day average volume:
8,156,624
83,434,571

CLASS ACTION UPDATE for OLPX, GNRC and TWST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

3:21 pm ET January 17, 2023 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OLPX Shareholders Click Here: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=35707&wire=1

GNRC Shareholders Click Here: https://www.zlk.com/pslra-1/generac-class-action-loss-submission-form?prid=35707&wire=1

TWST Shareholders Click Here: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35707&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Tuesday, January 17, 2023, Press release picture

Olaplex Holdings, Inc. (NASDAQ:OLPX)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Olaplex common stock pursuant and/or traceable to the Company's initial public offering conducted on or around September 30, 2021.

Lead Plaintiff Deadline : January 17, 2023

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=35707&wire=1

According to the filed complaint, (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the offering documents; and (iv) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.

Generac Holdings Inc. (NYSE:GNRC)

This lawsuit is on behalf of all investors who purchased or otherwise acquired Generac Holdings Inc. common stock between April 29, 2021, and November 1, 2022, inclusive.

Lead Plaintiff Deadline : January 30, 2023

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/generac-class-action-loss-submission-form?prid=35707&wire=1

According to the filed complaint, (1) despite defendant's claims that "safety is paramount", Generac's SnapRS units, which are components for rapidly shutting down solar devices in certain dangerous situations, were defective; (2) Generac did not timely record warranty liabilities resulting from the defective SnapRS units; and, (3) despite assurances to the contrary, the Company's sales to channel partners were highly concentrated in a single partner.

Twist Bioscience Corporation (NASDAQ:TWST)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.

Lead Plaintiff Deadline : February 10, 2023

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35707&wire=1

According to the filed complaint, 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist's synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company's true financial condition and prospects.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP





View source version on accesswire.com:

https://www.accesswire.com/735586/CLASS-ACTION-UPDATE-for-OLPX-GNRC-and-TWST-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



comtex tracking

COMTEX_422833098/2457/2023-01-17T15:21:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.